- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01423903
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
January 14, 2014 updated by: Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer
The purpose of this study is to determine whether OPB-51602 is safe and tolerable when given daily by mouth to subjects with advanced solid tumors.
Study Overview
Detailed Description
This study is based on data that support a role for the signal transducer and activator of transcription (STAT) family of proteins in oncogenesis.
One of the mechanisms of action of OPB-51602 includes inhibition of STAT3 phosphorylation.
Therefore OPB-51602 is expected to be active as an anti-cancer drug.
This first-in-human study will characterize the safety profile of OPB-51602, evaluate the pharmacokinetics of OPB-51602, identify a recommended phase II dose, and obtain preliminary efficacy data, in subjects with advanced cancers for whom there is no standard treatment available.
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Sarasota, Florida, United States, 34232
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects aged ≥ 18 years
- Pathologically confirmed advanced cancer that is resistant or refractory to standard therapy or for which no standard curative therapy is available
- At least 4 weeks since the last dose of prior chemotherapy, radiation therapy, or investigational agent.
- Subjects must have recovered from adverse effects of prior therapy at time of enrollment to ≤ Grade 1 (excluding alopecia)
- ECOG performance status ≤ 1
- Life expectancy of ≥ 3 months following study entry
Adequate organ function, defined as follows:
- Serum creatinine < 1.5 x the upper limit of normal (ULN)
- Aspartate aminotransferase and alanine aminotransferase levels ≤ 3.0 x ULN (≤ 5.0 x ULN in the presence of known liver metastasis)
- Total bilirubin ≤ 1.5 x ULN
- Alkaline phosphatase levels ≤ 2.5 x ULN (≤ 5 x ULN in presence of bone metastasis)
- Absolute neutrophil count of ≥ 1,500/mm³ (≥ 1.5 x 10⁹/L)
- Platelet count ≥ 100,000/mm³ (≥ 100 x10⁹/L)
- Hemoglobin ≥ 9 g/dL
- For women of childbearing potential (WOCBP), a negative serum pregnancy test result at screening and negative urine pregnancy test on Day 1
- WOCBP or men whose sexual partners are WOCBP must agree to use 2 methods of adequate contraception
- Before any protocol-specific screening procedures are performed, subjects must have signed and dated the IRB-approved ICF.
Exclusion Criteria:
- Uncontrolled concurrent illness, including ongoing or active infection, uncontrolled hypertension,or any other condition that could raise the subject's safety risk.
- Altered mental status, psychiatric illness, or social situation that could limit compliance with study requirements and/or confound interpretation of study results.
- Known infection with human immunodeficiency virus, hepatitis B, or hepatitis C.
- Known brain metastasis that has not been treated and stable for at least 4 weeks, or subjects with leptomeningeal disease.
- Subjects unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with absorption of oral drugs.
- A history of major surgery within 28 days of first receipt of study drug. Subjects must have recovered fully from any surgery.
- Nursing or pregnant women
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in opinion of investigator, contraindicates use of an investigational drug, or that may render subject at excessively high risk for treatment complications.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OPDC-51602
Subjects with advanced solid tumors will be treated with OPDC-51602 once daily by mouth
|
A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the safety and tolerability of OPB-51602
Time Frame: Weekly for first cycle, then every 2 weeks (on average up to 8 weeks).
|
AEs, vital signs, body weight, ECGs, clinical laboratory tests, and performance status will be assessed.
|
Weekly for first cycle, then every 2 weeks (on average up to 8 weeks).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the pharmacokinetics of OPB-51602 and to determine the MTD of OPB-51602
Time Frame: 28 days
|
The following PK parameters (Cmax, tmax, AUC₀-t, AUCtau, CLss/F and t½,z) will be determined using a non-compartmental approach for OPB-51602 and selected metabolites after single (Cycle 1, Day 1) and multiple daily doses (Cycle 2, Day 1).
|
28 days
|
Pharmacodynamic profile:
Time Frame: 28 days
|
Study drug effects on STAT-3 phosphorylation will be assessed in PBMCs of study subjects in the dose escalation and expansion stages.
|
28 days
|
Antitumor effects:
Time Frame: Every 2 cycles (on average 8 weeks).
|
Treatment response and/or disease progression in subjects with measurable disease will be evaluated after every 2 cycles using Response Evaluation Criteria in Solid Tumors (RECIST₉).
|
Every 2 cycles (on average 8 weeks).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Agnes Elekes, M.D., Otsuka Pharmaceutical Development & Commercialization, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
August 3, 2011
First Submitted That Met QC Criteria
August 24, 2011
First Posted (Estimate)
August 26, 2011
Study Record Updates
Last Update Posted (Estimate)
January 15, 2014
Last Update Submitted That Met QC Criteria
January 14, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 266-09-202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University Health Network, TorontoUniversity of UlmRecruiting
Clinical Trials on OPB-51602
-
Otsuka Pharmaceutical Co., Ltd.CompletedAcute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid LeukemiaJapan
-
National University Hospital, SingaporeOtsuka Pharmaceutical Co., Ltd.; Shin Nippon Biomedical Laboratories, Ltd.TerminatedNasopharyngeal CarcinomaSingapore
-
Otsuka Beijing Research InstituteCompletedMalignant Solid TumourSingapore
-
Otsuka Pharmaceutical Co., Ltd.CompletedHepatocellular CarcinomaJapan
-
Hospital Universitario 12 de OctubreApices Soluciones S.L.; Otsuka Pharmaceutical Co., Ltd.; Vivia BiotechCompletedAcute Myeloid LeukemiaSpain
-
Otsuka Beijing Research InstituteOtsuka Pharmaceutical Co., Ltd.UnknownNon-Hodgkin's Lymphoma(NHL) | Multiple Myeloma(MM)Hong Kong
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Korea Otsuka Pharmaceutical Co., Ltd.UnknownSolid TumorKorea, Republic of
-
Korea Otsuka Pharmaceutical Co., Ltd.Otsuka Pharmaceutical Co., Ltd.CompletedSolid TumorKorea, Republic of
-
National University Hospital, SingaporeOtsuka Pharmaceutical Co., Ltd.Unknown